Targeting a mirabegron precursor by BH3-mediated continuous flow reduction process

    Sonia De Angelisa, Claudia Carluccia, Modesto de Candiaa, Gabriele Rebuzzinib, Paolo Celestinib, Massimiliano Riscazzib, Renzo Luisia, Leonardo Degennaroa

    • a FLAME-Lab − Flow Chemistry and Microreactor Technology Laboratory, Department of Pharmacy — Drug Sciences, University of Bari “A. Moro” Via E. Orabona 4, Bari 70125, Italy
    • b COSMA S.p.A, Via Colleoni 15/17, Ciserano, BG 24040, Italy

    A continuous-flow reduction of (R)-2-hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide, involved in the synthetic pathway of Mirabegron, has been developed. This study demonstrated the possibility to safely handling BH3 complexes within microfluidic reactors using 2-MeTHF as greener alternative to traditional solvents, and without requiring any additive such as DMI. In addition, NMR and HPLC purity analysis revealed that the sole by-product of this process is the diamine 3, which wouldn’t affect the following synthetic steps towards Mirabegron.

    Read the publication that featured this abstract

    Get in touch

    For more information on flow chemistry systems and services please use the contact methods below.

    Call us on +44 (0)1284 728659 or Email us